MENU
WORLDALLERGY.ORG
Facebook: World Allergy Organization
Twitter: World Allergy Organization
LinkedIn: World Allergy Organization
Instagram: World Allergy Organization
Back to Top

Tralokinumab (anti-IL 13) found to be safe and well tolerated but failed to reduce asthma exacerbation in phase 2b trial